How High Glucose Damages the Body
The complications of diabetes are not random — they follow directly from what chronically elevated glucose does to blood vessels and nerves. Understanding the mechanism makes the complications less mysterious and the urgency of control more intuitive.
Glucose, at normal concentrations, is essential fuel. At chronically elevated concentrations, it becomes chemically damaging. It reacts with proteins throughout the body in a process called glycation — sugar molecules attach to proteins and alter their structure and function, much like rust alters metal. These damaged proteins accumulate in vessel walls, making them stiffer and less responsive. Elevated glucose also produces chemically unstable molecules called reactive oxygen species (free radicals) that damage cell membranes and trigger chronic inflammation. And it activates internal signaling pathways — particularly the polyol pathway and protein kinase C — that disrupt normal cell function in ways that compound silently over years.
The tissues most vulnerable are those that absorb glucose in direct proportion to how much is circulating in the blood, rather than using insulin as the gate. These include the cells lining tiny blood vessels (endothelial cells), the filtering units of the kidney (mesangial cells), the cells of the retina at the back of the eye, and nerve cells. This explains why the classic complications of diabetes cluster in exactly these locations: eyes, kidneys, nerves, and ultimately the large vessels supplying the heart and brain.
The Complications, Organ by Organ
Diabetic Retinopathy
Damage to the blood vessels of the retina — the leading cause of preventable blindness in working-age adultsThe retina is densely supplied by tiny blood vessels that are among the first to show damage from chronic hyperglycemia. Early retinopathy causes these vessels to leak (background retinopathy) — visible on eye exam but not yet affecting vision. Over time, the retina responds by growing new, fragile blood vessels that bleed easily (proliferative retinopathy), and fluid accumulates in the central retina (macular edema), which directly impairs vision.
After 20 years of diabetes, approximately 60–80% of patients have some degree of retinopathy detectable on examination, though not all progress to vision loss. The DCCT (Type 1) and UKPDS (Type 2) trials both demonstrated that intensive glucose control substantially reduces the risk of retinopathy development and progression — by approximately 76% in the DCCT over 6.5 years in Type 1 patients. Annual dilated eye exams are the standard of care, as early detection allows laser treatment and anti-VEGF injections before significant vision loss occurs.
Diabetic Nephropathy
Kidney damage — the leading cause of end-stage kidney disease requiring dialysis in the USThe kidney filters roughly 180 liters of blood per day through tiny filtering units called glomeruli. Chronic high blood sugar thickens the walls of these filters and causes them to leak protein — specifically a protein called albumin — into the urine (albuminuria). The earliest detectable sign is a small amount of albumin in the urine (microalbuminuria), which, if untreated, progresses to larger amounts (proteinuria) and eventually declining kidney function as measured by eGFR (estimated glomerular filtration rate — a blood test that reflects how well the kidneys are filtering).
Approximately 20–40% of people with diabetes develop some degree of kidney disease over time. Diabetic kidney disease is the leading cause of end-stage kidney disease — accounting for roughly 44% of new dialysis cases in the United States. SGLT2 inhibitors have transformed the kidney disease trajectory, cutting the annual rate of kidney function decline by approximately 51% in clinical trials (see Post 3 — Treatment). Blood pressure control targeting below 130/80 mmHg and ACE inhibitors or ARBs are the other key pillars of kidney protection.
Diabetic Neuropathy
Nerve damage — the most common complication, affecting up to 50% of people with diabetesPeripheral neuropathy — damage to the nerves of the hands and feet — is the most common diabetic complication, typically presenting as numbness, tingling, or burning pain that begins in the toes and feet and works upward ("stocking-glove" distribution). The mechanism involves both direct glucose toxicity to nerve fibers and damage to the tiny blood vessels that supply them. Autonomic neuropathy — damage to the nerves controlling involuntary functions — can cause gastroparesis (delayed stomach emptying), erectile dysfunction, orthostatic hypotension (dizziness on standing), and disordered sweating.
Unlike retinopathy and nephropathy, established peripheral neuropathy is largely irreversible — which is why prevention through glucose control matters more than treatment. Tight glucose control in the DCCT reduced the development of clinical neuropathy by approximately 60% over 6.5 years in Type 1 patients. Once neuropathy is present, treatment focuses on symptom management (gabapentin, duloxetine, pregabalin) and rigorous foot care to prevent the ulceration and infection that can lead to amputation.
Cardiovascular Disease
The leading cause of death in people with diabetes — two to four times more common than in the general populationDiabetes speeds up the buildup of plaque inside artery walls (atherosclerosis) through several mechanisms: glucose attaches to LDL cholesterol making it more inflammatory, the inner lining of blood vessels becomes damaged and less able to regulate blood flow (endothelial dysfunction), chronic low-level inflammation accumulates, and blood becomes more prone to clotting. The result is that people with diabetes have two to four times the risk of dying from a heart attack or stroke compared to people without diabetes at the same age — and cardiovascular disease is the leading cause of death in both Type 1 and Type 2.
The relationship between glucose control and heart outcomes is more complex than for eye, kidney, and nerve complications. The UKPDS showed that intensive control in Type 2 reduced heart attacks by about 16% over 10 years — a benefit that became clearer and larger in the 24-year follow-up. The landmark ACCORD trial found that pushing A1c aggressively below 6% actually increased death rates in high-risk patients — a critical finding that reshaped how we think about targets (discussed below). GLP-1 agonists and SGLT2 inhibitors are now the most important tools for reducing heart and vascular risk in Type 2, independent of their blood sugar effects.
Diabetic Foot Disease
The intersection of neuropathy and vascular disease — responsible for the majority of non-traumatic amputationsDiabetic foot complications arise from the convergence of two problems: neuropathy removes the protective sensation that would normally signal injury, while peripheral arterial disease (reduced blood flow to the feet) impairs healing. Small wounds that a person with intact sensation would feel and address go unnoticed, become infected, and in the context of poor circulation, fail to heal. The result — in severe cases — is gangrene and amputation.
Diabetes accounts for approximately 70% of non-traumatic lower extremity amputations in the United States. Annual foot exams, appropriate footwear, daily self-inspection of the feet, and prompt attention to any break in the skin are not optional extras in diabetes care — they are standard practice that prevents the most devastating complication of the disease.
What A1c Actually Measures — and What It Misses
The hemoglobin A1c (A1c) test measures the percentage of hemoglobin — the oxygen-carrying protein in red blood cells — that has glucose permanently attached to it. Because red blood cells live approximately 90–120 days, the A1c reflects average blood glucose over roughly the past three months. It is the most widely used measure of long-term glucose control in diabetes.
What it does not capture is variability. Two patients can have identical A1c values of 7.5% but very different glucose profiles — one with relatively stable glucose throughout the day, and one with wild swings between dangerously low hypoglycemia and very high post-meal spikes. The first patient is doing well; the second is at higher risk for both hypoglycemic events and the oxidative damage from glucose peaks, despite the same average number. This is why continuous glucose monitoring and the concept of "time-in-range" — the percentage of time glucose stays between 70 and 180 mg/dL — are increasingly recognized as important complements to A1c. We cover those in Post 7.
A1c can also be inaccurate in certain conditions: hemolytic anemia, iron deficiency, sickle cell trait, and other conditions affecting red blood cell lifespan all distort A1c readings in ways that can mislead. In these patients, fructosamine or continuous glucose monitoring data are better measures.
The Evidence on A1c Thresholds and Complications
Three landmark trials provide the foundation for what we know about glucose targets and outcomes. Each told us something different — and the ACCORD trial in particular changed the field. More recent follow-up data has deepened our understanding of how long the benefits of early control actually last.
DCCT/EDIC (Type 1): 1,441 patients randomized to intensive control (A1c ~7.2%) vs. conventional (A1c ~9.1%) for 6.5 years. Intensive control reduced retinopathy by 76%, nephropathy by 50%, and clinical neuropathy by 60%. The EDIC follow-up — now spanning more than 20 years past the trial's end — showed that these benefits persisted in full despite A1c levels converging between groups. The differences in complications during the DCCT entirely explained the differences seen in EDIC, confirming true metabolic memory. Macrovascular benefits also emerged in long-term follow-up. Hypoglycemia was three times more frequent in the intensive group during the trial.
UKPDS/UKPDS 91 (Type 2): 3,867 newly diagnosed patients followed for 10 years, then monitored for an additional 24 years post-trial (UKPDS 91, published 2024). During the trial, intensive control (A1c ~7.0%) vs. conventional (A1c ~7.9%) reduced microvascular complications by 25%. In the 10-year post-trial period, a 15% reduction in MI and 13% reduction in all-cause mortality emerged despite A1c convergence. Remarkably, the 24-year UKPDS 91 data showed these legacy effects did not wane — microvascular benefits (24% reduction) and macrovascular benefits remained undiminished nearly a quarter-century after the trial ended.
ACCORD (Type 2, High CV Risk): 10,251 patients randomized to intensive control (target A1c <6%, achieved ~6.4%) vs. standard (target 7.0–7.9%, achieved ~7.5%). Stopped early: all-cause mortality was higher in the intensive group (1.41% vs. 1.14% per year; absolute excess ~0.27% per year, NNH ~370 per year). Mechanism remains debated — hypoglycemia, rapid lowering, or specific drug combinations. This finding reshaped how we think about aggressive targets in high-risk patients. Notably, the legacy effect data from ACCORD showed no macrovascular benefit persisted, suggesting legacy effects are strongest when intensive control is achieved early and without excessive hypoglycemia.
Beyond the landmark trials, large observational studies have quantified complication risk at specific A1c levels. The relationship is curvilinear — the greatest absolute benefit comes from lowering very high A1c levels, but progressive benefit continues down to near-normal levels.
Microvascular complications (Type 2, large UK cohort):
- A1c 6.5–7.0%: Lowest risk for nephropathy — the reference range
- A1c 7.0–7.4%: Retinopathy risk increased (HR 1.31) and microalbuminuria risk increased (HR 1.55) vs. 6.5–6.9%
- A1c >9.6%: Nephropathy risk HR 1.27, neuropathy HR 1.55, retinopathy HR 1.66 — all vs. 6.5–7.5%
Microvascular complications (Type 1, Swedish registry):
- A1c >8.6%: Proliferative retinopathy risk HR 5.98, macroalbuminuria risk HR 3.43
- The HbA1c–outcome relationship is substantially steeper in Type 1 than Type 2 at higher A1c levels
Cardiovascular outcomes:
- Type 1: Each 1% increase in A1c increases the risk of heart and vascular disease by 22–31% and the risk of a major cardiovascular event (heart attack, stroke, or cardiovascular death) by 42%
- Type 2: Each 1% increase in A1c increases the risk of heart and vascular disease by approximately 24%
The 43–44% rule: Each 10% relative reduction in A1c (e.g., from 10% to 9%, or from 8% to 7.2%) reduces retinopathy progression risk by 43–44% — a consistent finding across both Type 1 and Type 2 trials. Every improvement counts, even partial ones.
The ACCORD signal is one of the most important findings in diabetes medicine of the last 30 years, and it's still underappreciated by patients. The message is not "good glucose control is dangerous" — it's that aggressive glucose-lowering in already high-risk patients, using drugs that can cause hypoglycemia, created more harm than benefit. The lesson is nuance, not nihilism: tighter is better up to a point, and that point depends on who the patient is, what medications are being used, and how much hypoglycemia risk is involved. GLP-1 agonists and SGLT2 inhibitors — which lower glucose without meaningful hypoglycemia risk — have genuinely shifted this calculus. The ACCORD concern was most relevant to sulfonylurea and insulin-driven tight control in fragile patients. The UKPDS 91 data, meanwhile, is remarkable: the benefit of good early control is still detectable 24 years later. That's metabolic memory. It's also the strongest argument I know for treating aggressively early, while the window is open.
A Special Note on Youth-Onset Type 2 Diabetes
One finding from the recent literature deserves its own section, because it runs counter to most patients' assumptions: young people diagnosed with Type 2 diabetes face a more aggressive complication course than their peers with Type 1 — not a milder one.
The TODAY study and subsequent analyses show that youth-onset Type 2 diabetes is characterized by faster beta-cell decline, greater insulin resistance, and a complication timeline that is compressed relative to adult-onset disease. Microvascular complications begin appearing at roughly 8 years after diagnosis — earlier than in duration-matched Type 1 patients. By a mean age of 26.4 years, 28% of youth-onset Type 2 patients have two or more complications simultaneously. The complication rate is 5.65 events per 1,000 person-years, compared to 2.19 in duration-matched Type 1 patients.
By mean age 26.4 years and mean disease duration 13.3 years (TODAY study and related data):
- 60% develop at least one microvascular complication
- Diabetic kidney disease: 19.9% — more than three times the rate in duration-matched Type 1 (5.8%)
- Retinopathy: 9.1% vs. 5.6% in Type 1 (OR 2.24)
- Peripheral neuropathy: 17.7% vs. 8.5% in Type 1 (OR 2.52)
- Microvascular event rate: 5.65 per 1,000 person-years vs. 2.19 in Type 1
The accelerated trajectory is thought to reflect the particularly aggressive insulin resistance and beta-cell failure pattern in youth-onset Type 2, compounded by the longer total lifetime exposure to hyperglycemia ahead of these patients.
When a young adult is diagnosed with Type 2 diabetes — and I see this more often than I did a decade ago — I treat it with the same urgency I would bring to any high-risk situation. The instinct to be reassuring ("you're young, you have time") is exactly backwards. These patients have the most to lose from poor early control and the most to gain from aggressive intervention while their biology is still responsive. GLP-1 agonists and lifestyle change in a 22-year-old with Type 2 is not the same conversation as in a 65-year-old — the stakes are higher and the opportunity is greater.
A1c, Average Glucose, and What the Numbers Mean Day to Day
Patients often ask what their A1c translates to in terms of daily blood sugar. The relationship is approximately linear — each 1 percentage point change in A1c corresponds to roughly 28–30 mg/dL change in average glucose.
Targets Are Personal: The Same Number Means Different Things for Different People
The standard A1c target for most adults with diabetes is below 7.0%. That's a reasonable population-level goal, and it's where the evidence from DCCT and UKPDS clusters. But it's not a universal prescription — and applying it rigidly to every patient causes harm at both ends of the spectrum.
Targets should be individualized based on several factors that are genuinely different from patient to patient:
Tighter targets may be appropriate when:
Young patients with long life expectancy: The legacy effect is real — good control early pays dividends for decades. A 35-year-old has 40+ years ahead in which microvascular complications could develop and accumulate. The investment in tight control is justified by the time horizon.
Short disease duration: Earlier in the disease, beta-cell function is better preserved, hypoglycemia is less frequent, and the benefit-to-risk ratio of tight control is more favorable.
No significant cardiovascular disease: The ACCORD concern was specific to high-cardiovascular-risk patients. In lower-risk patients, tighter targets do not carry the same mortality signal.
Using medications with low hypoglycemia risk: GLP-1 agonists and SGLT2 inhibitors can achieve A1c values in the 6–7% range with minimal hypoglycemia risk — a fundamentally different risk profile than achieving the same target with sulfonylureas or insulin.
Relaxed targets may be appropriate when:
Older adults with limited life expectancy: For a patient in their 80s with multiple comorbidities and a life expectancy of 5–7 years, the microvascular benefits of tight control — which take years to decades to materialize — may not be realizable. The harms of hypoglycemia (falls, fractures, cardiac events, loss of driving independence) are immediate and serious. An A1c target of 7.5–8.5% in this population is entirely defensible and often preferable.
Significant hypoglycemia history or unawareness: Patients who have lost the ability to sense low blood sugar (hypoglycemia unawareness) are at high risk for severe events. Relaxing the target to give a wider safety margin is appropriate.
Complex medical situations, cognitive impairment, or limited support: The cognitive and functional demands of tight glucose management are real. Patients who cannot safely monitor, adjust, or respond to low glucose should not be pushed to targets that increase that risk.
Established advanced complications: Once significant retinopathy, nephropathy, or cardiovascular disease is present, the calculus shifts — preventing further progression matters, but aggressive glucose lowering that risks hypoglycemia may not be the marginal intervention that changes outcomes most.
When I set an A1c target with a patient, I'm really answering two questions: what is the benefit horizon for this person, and what is the cost of getting there? A 45-year-old with newly diagnosed Type 2, no cardiovascular disease, and access to GLP-1 therapy has a long benefit horizon and a low cost — I'm aiming for 6.5–7.0%. An 82-year-old with heart failure, early dementia, and a history of falls is a completely different conversation — I'd rather have their A1c at 7.5–8.0% and have them safe and functional than at 6.8% with two hypoglycemic episodes a year. The number serves the person, not the other way around.
The Complication Timeline: What Happens When and Why It Matters
Complications do not appear overnight. They develop over years of sustained exposure to elevated glucose — which is why the window for intervention is real and meaningful, and why the legacy effect works in both directions. Good control early protects forward; poor control early leaves damage that persists even after control improves. The timelines below reflect typical adult-onset disease; youth-onset Type 2 runs faster, as described above.
Many of the most serious complications of diabetes — retinopathy, nephropathy, neuropathy — are largely silent in their early stages. Patients feel well and have no symptoms while active damage is occurring. This is why surveillance matters: annual eye exams, annual urine albumin testing, regular eGFR checks, foot exams at every visit, and blood pressure monitoring are not bureaucratic box-checking. They are the tools that catch problems while they are still preventable or reversible. Don't skip them because you feel fine.
Beyond A1c: The Other Numbers That Matter
A1c gets the most attention, but it is one of several values that together determine complication risk in diabetes. The others are often undertreated — and in some patients, treating them matters as much or more than tightening glucose control.
Statins in diabetes: the evidence for starting early
People with diabetes have two to four times the baseline cardiovascular risk of people without it — which means a given cholesterol-lowering treatment produces a larger absolute benefit in this population than in lower-risk groups. The evidence for statins in diabetes is strong, and the current (2026) ACC/AHA guidelines recommend moderate-intensity statin therapy for essentially all adults with diabetes aged 40–75, regardless of their starting LDL level.
CARDS trial (primary prevention — patients with Type 2 but no prior heart disease): Atorvastatin 10mg vs. placebo over 4 years. Major cardiovascular events occurred in 10% of placebo patients vs. ~6.3% in the statin group. Absolute risk reduction: 3.7%. Number needed to treat (NNT): 27 — meaning 27 patients treated for 4 years prevents one heart attack, stroke, or cardiovascular death. That is a meaningful benefit for a primary prevention drug.
Heart Protection Study (diabetes subgroup without prior vascular disease): Simvastatin vs. placebo over 5 years. Major vascular events: 13.5% placebo vs. 9.3% statin. Absolute risk reduction: ~4.2%. NNT: ~24.
Meta-analysis (403,411 patients with Type 2 diabetes): Statin therapy reduced the risk of major cardiovascular events by 30% in relative terms. Absolute risk reduction for major events: 3.2% (NNT ~31). Absolute risk reduction for death from any cause: 5.2%. Benefit was greatest in patients with LDL above 130 mg/dL at the start of treatment.
The key principle: Statin benefit in diabetes is proportional to the LDL reduction achieved — each 39 mg/dL reduction in LDL produces a 21–22% reduction in major vascular events. There is no threshold below which the benefit disappears. This applies similarly in Type 1 and Type 2 diabetes.
Albumin in the urine: an early warning sign that warrants action
Microalbuminuria — a small but abnormal amount of the protein albumin appearing in the urine — is one of the most actionable early findings in diabetes. It signals that the kidney's filtration barrier is beginning to leak, usually from a combination of glucose damage and high blood pressure. Left unaddressed, it tends to worsen progressively toward more significant kidney damage.
When microalbuminuria appears, several things should happen promptly. Blood pressure should be optimized, and an ACE inhibitor or ARB started if not already prescribed — these medications specifically reduce pressure inside the kidney's filtering units and have been shown to slow albumin progression independent of their blood pressure effect. And if the patient is not already on an SGLT2 inhibitor, this is a strong indication to start one. The ADA and KDIGO guidelines now recommend SGLT2 inhibitors for most patients with Type 2 diabetes and any degree of chronic kidney disease starting at eGFR ≥20, regardless of whether A1c is already at target — the kidney and heart protection is the reason to use them, not the glucose lowering. As covered in Post 3 — Treatment, SGLT2 inhibitors cut the annual rate of kidney function decline by approximately 51% and reduce the risk of reaching kidney failure by 34%.